GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Pharma-Bio Serv Inc (OTCPK:PBSV) » Definitions » Free Cash Flow

PBSV (Pharma-Bio Serv) Free Cash Flow : $-1.88 Mil (TTM As of Jan. 2025)


View and export this data going back to 2006. Start your Free Trial

What is Pharma-Bio Serv Free Cash Flow?

Pharma-Bio Serv's total free cash flow for the months ended in Jan. 2025 was $-0.43 Mil. Its total free cash flow for the trailing twelve months (TTM) ended in Jan. 2025 was $-1.88 Mil.

Pharma-Bio Serv's Free Cash Flow per Share for the months ended in Jan. 2025 was $-0.02. Its free cash flow per share for the trailing twelve months (TTM) ended in Jan. 2025 was $-0.08.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Pharma-Bio Serv was -207.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Free Cash Flow Growth Rate using Free Cash Flow per Share data.

During the past 13 years, Pharma-Bio Serv's highest 3-Year average Free Cash Flow per Share Growth Rate was 438.30% per year. The lowest was -78.40% per year. And the median was 5.60% per year.


Pharma-Bio Serv Free Cash Flow Historical Data

The historical data trend for Pharma-Bio Serv's Free Cash Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma-Bio Serv Free Cash Flow Chart

Pharma-Bio Serv Annual Data
Trend Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
Free Cash Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.46 0.79 0.57 1.88 -0.73

Pharma-Bio Serv Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Free Cash Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.73 -0.70 -0.67 -0.08 -0.43

Pharma-Bio Serv Free Cash Flow Calculation

Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company.

Pharma-Bio Serv's Free Cash Flow for the fiscal year that ended in Oct. 2024 is calculated as

Free Cash Flow (A: Oct. 2024 )=Cash Flow from Operations+Capital Expenditure
=-0.567+-0.16
=-0.73

Pharma-Bio Serv's Free Cash Flow for the quarter that ended in Jan. 2025 is calculated as

Free Cash Flow (Q: Jan. 2025 )=Cash Flow from Operations+Capital Expenditure
=-0.429+0
=-0.43

Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharma-Bio Serv  (OTCPK:PBSV) Free Cash Flow Explanation

Free Cash Flow is very close to Warren Buffett's definition of Owner's Earnings, except that in Warren Buffett's Owner's Earnings, the spending for Property, Plant, and Equipment is only for maintenance (replacement), while in the Free Cash Flow calculation, the cost of new Property, Plant, and Equipment due to business expansion is also deducted. There, Free Cash Flow is more conservative than Owner's Earnings.

In Don Yacktman's calculation of forward rate of return, he uses Free Cash Flow for the calculation. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation.

This is what Yacktman said in his March 2012 interview - when the S&P 500 was at 1400:

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is because research shows that five years is the length of the typical business cycle.

Therefore, as of Jan25, Pharma-Bio Serv's Forward Rate of Return (Yacktman) % is

Forward Rate of Return (Yacktman) % (Jan25)=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0.08533333/0.6+-0.3244
=-18.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Free Cash Flow within a report period can be affected by management's decisions of capital spending. Therefore, it is important to look at long term when it comes to Free Cash Flow.


Pharma-Bio Serv Free Cash Flow Related Terms

Thank you for viewing the detailed overview of Pharma-Bio Serv's Free Cash Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma-Bio Serv Business Description

Traded in Other Exchanges
N/A
Address
No. 6 Road 696, Pharma-Bio Serv Building, Dorado, PRI, 00646
Pharma-Bio Serv Inc is a compliance and technology transfer services consulting firm. It also provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. It has three reportable segments: Puerto Rico technical compliance consulting which is the key revenue driver; United States technical compliance consulting; and Europe technical compliance consulting. The company offers solutions to the pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies. It generates maximum revenue from Puerto Rico and also has its presence in United States, Europe and Other countries.
Executives
Elizabeth Plaza 10 percent owner 363 DORADO BEACH EAST, DORADO PR 00646
Altura Victor Sanchez officer: President and CEO C/O PHARMA-BIO SERV, INC., 6 ROAD 696, DORADO PR 00646
San Juan Holdings 10 percent owner 255 PONCE DE LEON, SUITE 305 MCS PLAZA, SAN JUAN PR 00917
Pedro J Lasanta officer: Chief Financial Officer 373 MENDEZ VIGO, STE 110, DORADO PR 00646
Dov Perlysky director 2 LAKESIDE DRIVE WEST, LAWRENCE NY 11559
L P Venturetek 10 percent owner C/O DAVID SELENGUT ELLENOFF GROSSMAN, 370 LEXINGTON AVENUE 19TH FLOOR, NEW YORK NY 10017
Barron Partners Lp 10 percent owner 730 FIFTH AVENUE, 25TH FLOOR, NEW YORK NY 10019
Manuel O Morera officer: Chief Financial Officer 373 MENDEZ VIGO, SUITE 110, DORADO PR 00646
Mark A Fazio officer: Exec. Vice President and COO P O BOX 1026 GREEN STREET, PERKASIE PA 18944
Kirk Wheeler Michel director 209 EAST TRYON STREET, HILLSBOROUGH NC 27278
Irving L Wiesen director 1273 NORTH AVENUE, APT 1E 7, NEW ROCHELLE NY 10804
Howard Spindel director 39 BROADWAY SUITE 3300, NEW YORK NY 10028
Nelida Plaza Rodriguez officer: Vice President and Secretary G11 CALLE MADRE PERLA URB, DORADO DEL MAR, DORADO PR 00646
Krovim Llc director, 10 percent owner, officer: Manager P.O. BOX 339, LAWRENCE NY 11559